POSEIDA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.13 USD | +3.90% |
|
+5.45% | -36.61% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 678.2 | 425.7 | 455.5 | 321.3 | 206.5 | - | - |
| Enterprise Value (EV) 1 | 678.2 | 425.7 | 455.5 | 321.3 | 206.5 | 206.5 | 206.5 |
| P/E ratio | -3.04 x | -3.39 x | -5.96 x | -2.45 x | -1.24 x | -1.18 x | -1.29 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 13.6 x | 3.49 x | 4.97 x | 4.42 x | 9.72 x | 37.2 x |
| EV / Revenue | - | 13.6 x | 3.49 x | 4.97 x | 4.42 x | 9.72 x | 37.2 x |
| EV / EBITDA | -5,470,709 x | -3,110,265 x | -8,316,569 x | - | - | - | - |
| EV / FCF | -5.21 x | -4.05 x | -14.8 x | -3.37 x | -1.54 x | -1.26 x | -1.15 x |
| FCF Yield | -19.2% | -24.7% | -6.74% | -29.6% | -64.9% | -79.4% | -87.2% |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 61,820 | 62,506 | 85,949 | 95,624 | 96,928 | - | - |
| Reference price 2 | 10.97 | 6.810 | 5.300 | 3.360 | 2.130 | 2.130 | 2.130 |
| Announcement Date | 3/11/21 | 3/10/22 | 3/9/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 31.24 | 130.5 | 64.7 | 46.67 | 21.25 | 5.55 |
| EBITDA | - | -124 | -136.9 | -54.77 | - | - | - | - |
| EBIT 1 | - | -126.5 | -141.4 | -59.95 | -129.5 | -177.9 | -221.5 | -233.3 |
| Operating Margin | - | - | -452.69% | -45.94% | -200.15% | -381.28% | -1,042.53% | -4,202.99% |
| Earnings before Tax (EBT) 1 | - | -129.8 | -125 | -63.46 | -123.3 | -183.8 | -230.2 | -237.1 |
| Net income 1 | - | -129.8 | -125 | -64 | -123.4 | -183.8 | -230.2 | -237.1 |
| Net margin | - | - | -400.07% | -49.05% | -190.76% | -393.85% | -1,083.2% | -4,271.36% |
| EPS 2 | -5.500 | -3.610 | -2.010 | -0.8900 | -1.370 | -1.720 | -1.808 | -1.650 |
| Free Cash Flow 1 | - | -130.2 | -105.2 | -30.7 | -95.23 | -134 | -164 | -180 |
| FCF margin | - | - | -336.7% | -23.52% | -147.18% | -287.14% | -771.76% | -3,243.24% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 6/19/20 | 3/11/21 | 3/10/22 | 3/9/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 31.24 | 1.435 | 2.7 | 116.3 | 10.05 | 10.34 | 20.01 | 9.352 | 25 | 11.67 | 11.67 | 11.67 | 11.67 | 7.5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -41.59 | -17.48 | -56.96 | -41.54 | 71.78 | -33.22 | -39.52 | -27.86 | -36.22 | -25.91 | -41.71 | -43.98 | -44.73 | -47.25 | -54.5 |
| Operating Margin | - | -55.95% | -3,969.41% | -1,538.7% | 61.72% | -330.52% | -382.06% | -139.18% | -387.32% | -103.66% | -357.51% | -376.97% | -383.4% | -405% | -726.67% |
| Earnings before Tax (EBT) 1 | -42.42 | 1.469 | -58.06 | -43.04 | 70.66 | -33.03 | -38.85 | -27.46 | -31.67 | -25.35 | -42.38 | -44.7 | -45.5 | -48.08 | -57.25 |
| Net income 1 | -42.42 | 1.469 | -58.06 | -43.04 | 70.41 | -33.32 | -38.85 | -27.46 | -31.78 | -25.35 | -42.38 | -44.7 | -45.5 | -48.08 | -57.25 |
| Net margin | - | 4.7% | -4,045.78% | -1,593.93% | 60.54% | -331.49% | -375.59% | -137.19% | -339.8% | -101.42% | -363.3% | -383.19% | -390.04% | -412.07% | -763.33% |
| EPS 2 | -0.6800 | 0.0200 | -0.9300 | -0.6900 | 0.9200 | -0.3900 | -0.4500 | -0.3200 | -0.3500 | -0.2700 | -0.4200 | -0.4325 | -0.4175 | -0.4075 | -0.4300 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/9/21 | 3/10/22 | 5/12/22 | 8/11/22 | 11/10/22 | 3/9/23 | 5/9/23 | 8/8/23 | 11/9/23 | 3/7/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -130 | -105 | -30.7 | -95.2 | -134 | -164 | -180 |
| ROE (net income / shareholders' equity) | - | -231% | -59.8% | -37.2% | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | -3.150 | -1.650 | -0.3700 | - | - | - | - |
| Capex 1 | - | 16.9 | 2.63 | 3.92 | 3.07 | 4 | 4.05 | 4.4 |
| Capex / Sales | - | - | 8.43% | 3.01% | 4.74% | 8.57% | 19.06% | 79.28% |
| Announcement Date | 6/19/20 | 3/11/21 | 3/10/22 | 3/9/23 | 3/7/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.13
USD
Average target price
14
USD
Spread / Average Target
+557.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -36.61% | 206M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- PSTX Stock
- Financials Poseida Therapeutics, Inc.
